New York State Assembly

 
•  Summary 
 
•  Actions 
 
•  Committee Votes 
 
•  Floor Votes 
 
•  Memo 
 
•  Text 
 
•  LFIN 
 
•  Chamber Video/Transcript 

A01017 Summary:

A01017 Actions:

A01017 Committee Votes:

Committee:RULES   Chair:Glick      
DATE:01/14/2025AYE/NAY:29/0  Action: Favorable         
Heastie
Excused
Barclay
Aye
Pretlow
Aye
Hawley
Aye
Cook
Aye
Blankenbush
Aye
Glick
Aye
Ra
Aye
Dinowitz
Aye
Brabenec
Aye
Colton
Aye
Palmesano
Aye
Magnarelli
Aye
Reilly
Aye
Paulin
Aye
Smith
Aye
Peoples-Stokes
Aye
Jensen
Aye
Benedetto
Aye
Lavine
Aye
Lupardo
Aye
Braunstein
Aye
Davila
Excused
Hyndman
Aye
Rozic
Aye
Bronson
Aye
Hevesi
Aye
Hunter
Aye
Taylor
Aye
Cruz
Aye
Vanel
Aye

Committee:HEALTH   Chair:Paulin      
DATE:01/14/2025AYE/NAY:25/0  Action: Favorable refer to committee Rules        
Paulin
Aye
Jensen
Aye
Dinowitz
Aye
Gandolfo
Aye
Rosenthal
Aye
Blumencranz
Aye
Hevesi
Aye
Gray
Excused
Steck
Aye
Maher
Aye
Braunstein
Aye
Slater
Aye
Solages
Aye
Chludzinski
Aye
Bichotte Hermel
Aye
Norber
Aye
Sayegh
Aye
McDonald
Aye
Reyes
Aye
Gonzalez-Rojas
Aye
Rajkumar
Aye
Forrest
Aye
Kelles
Aye
Lucas
Aye
Meeks
Aye
Lunsford
Aye

A01017 Floor Votes:

A01017 Memo:

NEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
 submitted in accordance with Assembly Rule III, Sec 1(f)



 
BILL NUMBER: A1017
 
SPONSOR: Paulin

 
TITLE OF BILL:
 
An act to amend the public health law, in relation to authorizing the
health care and wellness education and outreach program to develop and
disseminate information regarding drug-induced movement disorders
 
 
PURPOSE:
 
To make changes to the requirements on provided information related to
telehealth and reducing stigma for people living with drug induced move-
ment disorders.
 
 
SUMMARY OF PROVISIONS:
 
This bill would clarify that information regarding drug-induced movement
disorders will be developed by the Department of Health in consultation
with the Office of Mental Health and disseminated by the Department of
Health.
 
 
JUSTIFICATION:
 
Patients receiving treatment with medications for their mental health
conditions may be at risk of developing a drug-induced movement disorder
These involuntary movement disorders are caused by medications that help
control dopamine, such as first- and second-generation antipsychotics
commonly prescribed to treat people living with mental illnesses. Some
drug-induced movement disorders, such as tardivedyskinesia; are persist-
ent, irreversible- potentially disabling neurological conditions charac-
terized by uncontrollable repetitive movements of the face, torso, or
other parts of the body.  While untreated involuntary movements can be
stigmatizing and debilitating, the rates of undiagnosed patients living
with drug-induced movement disorders remains high.
 
 
LEGISLATIVE HISTORY:
 
This is a new bill.
 
 
BUDGET IMPLICATIONS:  None noted.
 
 
EFFECTIVE DATE:
This act shall take effect on the same date and in the same manner as a
chapter of the laws of 2024 amending the public health law relating to
establishing a drug-induced movement disorder screening education
program, as proposed in legislative bills numbers S. 8965-A 8 and A.
6799-B, takes effect

A01017 Text:

 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          1017
 
                               2025-2026 Regular Sessions
 
                   IN ASSEMBLY
 
                                       (Prefiled)
 
                                     January 8, 2025
                                       ___________
 
        Introduced by M. of A. PAULIN -- read once and referred to the Committee
          on Health
 
        AN  ACT  to  amend the public health law, in relation to authorizing the
          health care and wellness education and outreach program to develop and
          disseminate information regarding drug-induced movement disorders

          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section 1. Paragraph (h) of subdivision 1 of section 207 of the public
     2  health  law,  as  added  by  a  chapter of the laws of 2024 amending the
     3  public health law  relating  to  establishing  a  drug-induced  movement
     4  disorder  screening  education program, as proposed in legislative bills
     5  numbers S. 8965-A and A. 6799-B, is amended to read as follows:
     6    (h) [The department shall develop and  conduct  a  program  concerning
     7  drug-induced]  Drug-induced  movement  disorders[.  Such  program  shall
     8  include but not be limited to, (i) educational information on],  includ-
     9  ing the importance of screening for and identifying symptoms of drug-in-
    10  duced movement disorders[; and (ii) the development and dissemination of
    11  educational materials for healthcare providers regarding], treatment for
    12  drug-induced  movement  disorders,  [including for services provided via
    13  telehealth.  Such] and information on methods by which the stigma  expe-
    14  rienced by people living with drug-induced movement disorders related to
    15  the  treatment of mental health conditions may be reduced or eliminated.
    16  Any such educational  materials  disseminated  to  healthcare  providers
    17  shall  be  developed  [and] in consultation with the commissioner of the
    18  office of mental health, disseminated by the department in  coordination
    19  with  relevant  healthcare provider groups, and shall include best prac-
    20  tices for the treatment and screening of movement disorders informed  by
    21  the  American  Psychiatric  Association  and  other professional society
    22  practice guidelines.   [Such program shall also  include  education  and
    23  outreach  on  the  elimination of stigma for people living with drug-in-

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD02693-01-5
        A. 1017                             2

     1  duced movement disorders related  to  the  treatment  of  mental  health
     2  conditions.]
     3    §  2.  This  act  shall  take  effect on the same date and in the same
     4  manner as a chapter of the laws of 2024 amending the public  health  law
     5  relating  to  establishing  a  drug-induced  movement disorder screening
     6  education program, as proposed in legislative bills  numbers  S.  8965-A
     7  and A. 6799-B, takes effect.

A01017 LFIN:

 
NO LFIN

A01017 Chamber Video/Transcript: